Oncotarget

Clinical Research Papers:

Identification of prostate cancer biomarkers in urinary exosomes

Anders Øverbye, Tore Skotland, Christian J. Koehler, Bernd Thiede, Therese Seierstad, Viktor Berge, Kirsten Sandvig and Alicia Llorente _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:30357-30376. https://doi.org/10.18632/oncotarget.4851

Metrics: PDF 2802 views  |   HTML 3063 views  |   ?  


Abstract

Anders Øverbye1,2, Tore Skotland1,2, Christian J. Koehler3,4, Bernd Thiede3,4, Therese Seierstad5, Viktor Berge6, Kirsten Sandvig1,2,4 and Alicia Llorente1,2

1 Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway

2 Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway

3 The Biotechnology Centre of Oslo, University of Oslo, Oslo, Norway

4 Department of Biosciences, University of Oslo, Oslo, Norway

5 Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway

6 Department of Urology, Oslo University Hospital, Oslo, Norway

Correspondence to:

Alicia Llorente, email:

Keywords: biomarkers, exosomes, extracellular vesicles, mass spectrometry, prostate cancer

Received: April 30, 2015 Accepted: June 23, 2015 Published: July 13, 2015

Abstract

Exosomes have recently appeared as a novel source of non-invasive cancer biomarkers since tumour-specific molecules can be found in exosomes isolated from biological fluids. We have here investigated the proteome of urinary exosomes by using mass spectrometry to identify proteins differentially expressed in prostate cancer patients compared to healthy male controls. In total, 15 control and 16 prostate cancer samples of urinary exosomes were analyzed. Importantly, 246 proteins were differentially expressed in the two groups. The majority of these proteins (221) were up-regulated in exosomes from prostate cancer patients. These proteins were analyzed according to specific criteria to create a focus list that contained 37 proteins. At 100% specificity, 17 of these proteins displayed individual sensitivities above 60%. Even though several of these proteins showed high sensitivity and specificity for prostate cancer as individual biomarkers, combining them in a multi-panel test has the potential for full differentiation of prostate cancer from non-disease controls. The highest sensitivity, 94%, was observed for transmembrane protein 256 (TM256; chromosome 17 open reading frame 61). LAMTOR proteins were also distinctly enriched with very high specificity for patient samples. TM256 and LAMTOR1 could be used to augment the sensitivity to 100%. Other prominent proteins were V-type proton ATPase 16 kDa proteolipid subunit (VATL), adipogenesis regulatory factor (ADIRF), and several Rab-class members and proteasomal proteins. In conclusion, this study clearly shows the potential of using urinary exosomes in the diagnosis and clinical management of prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4851